- FDA approval of Biogen’s Aduhelm for Alzheimer’s should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs.
- The rerating of Biogen shares following the FDA decision demonstrates the potential of innovation in the biopharmaceutical industry to generate significant alpha for investors.
- We see gene therapy, rare diseases, and oncology, as well as advanced diagnostic testing as other areas where R&D spending is leading to scientific breakthroughs with the potential to create new, large addressable treatment markets and address unmet needs.
For further details see:
Alzheimer's Approval Validates Biopharmaceutical Innovation